Estrogen-receptor status in breast cancer -: Reply

被引：0

作者：

Cummings, SR ^{[1
]}

Grady, D

Black, D

Eckert, S

Krueger, KA

Nickélsen, T

Glusman, JE

Powles, TJ

Cauley, JA

Norton, L

Bjarnason, NH

Morrow, M

Jordan, VC

Lippman, ME

Costa, A

机构：

[1] Prevent Sci Grp, San Francisco, CA USA

[2] Eli Lilly & Co, Indianapolis, IN 46285 USA

[3] Royal Marsden NHS Trust Hosp, Sutton, Surrey, England

[4] Univ Pittsburgh, Pittsburgh, PA USA

[5] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[6] Ctr Clin & Basic Res, Ballerup, Denmark

[7] Northwestern Univ, Sch Med, Chicago, IL USA

[8] Georgetown Univ, Med Ctr, Washington, DC 20007 USA

[9] European Inst Oncol, Milan, Italy

来源：

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2000年 / 283卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：338 / 339

页数：2

共 5 条

[1]

CLARK GM, 1993, CANCER-AM CANCER SOC, V71, P2157, DOI 10.1002/1097-0142(19930315)71:6+<2157::AID-CNCR2820711606>3.0.CO

[2]

2-O

[3] The effect of raloxifene on risk of breast cancer in postmenopausal women - Results from the MORE randomized trial [J].

Cummings, SR ;

Eckert, S ;

Krueger, KA ;

Grady, D ;

Powles, TJ ;

Cauley, JA ;

Norton, L ;

Nickelsen, T ;

Bjarnason, NH ;

Morrow, M ;

Lippman, ME ;

Black, D ;

Glusman, JE ;

Costa, A ;

Jordan, VC .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (23) :2189-2197

[4]

*EARL BREAST CANC, 1999, LANCET, V351, P1451

[5]

MCGUIRE WL, 1992, NEW ENGL J MED, V326, P1756

← 1 →